ArticleGut2017
Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.
Article in Gut, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 158 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
158 citing papers in PubMed, 5 syntheses or guidelines pooled it, 238 citations in OpenAlex.
- PD-L1 and the Clinical Outcomes of Ovarian Cancer: Meta-Analysis and Bioinformatical Analysis.Asian Pacific journal of cancer prevention : APJCP · 2022Pooled it
- Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis.International journal of colorectal disease · 2021Pooled it
- Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis.Disease markers · 2020Pooled it
- The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Pooled it
- Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2019Pooled it
- Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.Molecular oncology · 2022Trial
- Immune Checkpoint-Based Therapies in Colorectal Cancer-Current Approaches and Future Perspectives.International journal of molecular sciences · 2026Review
- Bidirectional Interactions Between Immune Regulation and the Insulin-like Growth Factor Axis in Colorectal Cancer.International journal of molecular sciences · 2026Review
- Tumor-cell PD-L1 expression, mismatch repair status, and survival outcomes in colorectal carcinoma: a retrospective Pakistani cohort study.Frontiers in oncology · 2026Article
- Stem cell activation in organ culture reveals novel transcriptional programs underlying metabolic, fibrotic, vascular, and immune dysregulation in uterine leiomyomas.Frontiers in cell and developmental biology · 2026Article
- Integrating COX-2, stromal PD-L1, and T-cell infiltration enhances prognostic stratification in colorectal cancer.BMC cancer · 2025Article
- Computationally Designed Nanobinders as Affinity Ligands in Diagnostic and Therapeutic Applications.Journal of the American Chemical Society · 2025Article
- Co-Infection by Porphyromonas gingivalis and Fusobacterium nucleatum Increases PD-L1 Expression in Esophageal Cancer Tissues.MicrobiologyOpen · 2025Article
- Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?Journal of experimental & clinical cancer research : CR · 2025Review
- Immunohistochemical Profiling of Immune Checkpoints in Chronic Hepatitis B Liver Tissue.Pathogens (Basel, Switzerland) · 2025Article
- Immunohistochemical expression of PD-L1 in colorectal carcinoma among black patients and the clinicopathological correlates: a cross-sectional study.BMC gastroenterology · 2025Article
- A protease-cleavable liposome for co-delivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice.Nature communications · 2025Article
- MicroRNA 320a-3p up-regulation reduces PD-L1 expression in gastric cancer cells: an experimental and bioinformatic study.Scientific reports · 2025Article
- Review
- PD-L1 promotes tumor metastasis by regulating the infiltration of FGFBP2(+)Tm cells in colorectal cancer.Oncogene · 2025Article
98 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 7 institutions in 3 countries.
Funding
Abstract
objectiveEvidence suggests that CD274 (programmed death-ligand 1, B7-H1) immune checkpoint ligand repress antitumour immunity through its interaction with the PDCD1 (programmed cell death 1, PD-1) receptor of T lymphocytes in various tumours. We hypothesised that tumour CD274 expression levels might be inversely associated with T-cell densities in colorectal carcinoma tissue.
designWe evaluated tumour CD274 expression by immunohistochemistry in 823 rectal and colon cancer cases within the Nurses' Health Study and Health Professionals Follow-up Study. We conducted multivariable ordinal logistic regression analyses to examine the association of tumour CD274 expression with CD3
resultsCD274 expression in tumour cells or stromal cells (including immune cells) was detected in 731 (89%) or 44 (5%) cases, respectively. Tumour CD274 expression level correlated inversely with FOXP3
conclusionsTumour CD274 expression is inversely associated with FOXP3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.